ITEK Inotek Pharmaceuticals Corporat

1.75
-0.05  -3%
Previous Close 1.80
Open 1.80
Price To book 0.77
Market Cap 47.23M
Shares 26,986,000
Volume 333,735
Short Ratio 2.77
Av. Daily Volume 878,827

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 2 recruitment completed - noted April 11, 2017. Data due July 2017.
Trabodenoson and latanoprost
Glaucoma

Latest News

  1. Inotek Pharmaceuticals reports 1Q loss
  2. Inotek Pharmaceuticals Corporation Reports First Quarter 2017 Financial Results and Operational Highlights
  3. Inotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting
  4. Kalytera Reports FY 2016 Results; Provides Corporate Update and 2017 Outlook
  5. Blog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma
  6. Inotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-dose Combination (FDC) of Trabodenoson and Latanoprost
  7. Inotek Pharmaceuticals Financial Review Potential Value Drivers and Drug Pipeline
  8. Inotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational Highlights
  9. Today's Research Reports on Biotech Stocks to Watch: Inotek Pharmaceuticals and Tetraphase Pharmaceuticals
  10. 24 HOUR DEADLINE NOTICE FOR ITEK INVESTORS: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  11. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline - March 7, 2017
  12. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017 - ITEK
  13. Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Inotek Pharmaceuticals Corporation Investors and Encourages Investors to Contact the Firm
  14. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline - March 7, 2017
  15. INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  16. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017 – ITEK
  17. Inotek Pharmaceuticals Announces Participation at Upcoming Investor Conferences
  18. EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  19. URGENT: Monteverde & Associates PC Invites Inotek Pharmaceuticals Corporation Shareholders with Losses To Contact The Firm Immediately - ITEK